e-Drug3D

1618

AFATINIB

INN
AFATINIB

cas 850140-72-6

CLASS

ANTINEOPLASTIC
TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER
TYROSINE KINASE INHIBITOR
COVALENTLY BINDS TO THE KINASE DOMAINS OF EGFR (ERBB1), HER2 (ERBB2), AND HER4 (ERBB4) AND IRREVERSIBLY INHIBITS TYROSINE KINASE AUTOPHOSPHORYLATION, RESULTING IN DOWNREGULATION OF ERBB SIGNALING

ROUTE (list)

ORAL

ATC code

L01EB03

PK parameters

F 92 PERCENT
Tmax 3.5 HOUR
PPB 95 PERCENT
t1/2 37 HOUR

Solubility

SOLUBLE IN WATER

Target

TARGET EGFR (ERBB1)
HER2 (ERBB2)
HER4 (ERBB4)

PDB
4G5J (CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992)

Ligand code = 0WM (link to the list of PDB complexes)

Download experimental 3D coordinates of 0WM with added hydrogens

DrugCentral

Epidermal growth factor receptor UNIPROT P00533 EGFR

Receptor tyrosine-protein kinase erbB-2 UNIPROT P04626 ERBB2

Download SDF file

2-Butenamide,N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-,(2E)-

Formula:
C24H25ClFN5O3

Calculated chemical properties:

MW 485.94
NB_atoms 34
XLogP 4.39
PSA 83.462
NB_HD 2
NB_HA 8
fsp3 0.29
Lipinski(0=no;1=yes) 1

FDA
NDA 201292 (label) INN (AFATINIB DIMALEATE) GILOTRIF (BOEHRINGER INGELHEIM) APPROVAL= AP YEAR= 2013 NEWMOLECULARENTITY
NDA 210804 (pdf not found) INN (AFATINIB) AFATINIB (MSN PHARMACEUTICALS INC) APPROVAL= TA YEAR= 2023